Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Multiple Myeloma Physicians

Articles with lock require a subscription to GLG News | Request a free trial
May 19, 2008
Proteosome Inhibition with Carfilzomib is Promising Therapeutic Avenue
Analysis of: Proteolix Initiates Phase 2 Clinical Trial of Carfilzomib in Patients with Relapsed Solid Tumors | www.pipelinereview.com
Author: Michael Grossbard, Professor of Clinical Medicine, Columbia University College of Physicians and Surgeons
Carfilzomib is a nvelo prteosome inhibitor.  Bortezomib, the only proteosome inhibitor that is currently FDA approve, has shown significant activity in myeloma and mantle cell NHL and is being tested in other hematologic malignancies.  If Carfilzomib has improved toxicty and greater efficacy...
Brian AbbottMay 19, 2008
TREANDA for CLL could be a winner
Analysis of: FDA Accepts TREANDA(R) New Drug Application for the Treatment of Relapsed Indolent Non-Hodgkin's Lymphoma | www.pipelinereview.com
Author: Brian Abbott, Medical Director of Hematology, Big Sky Oncology
The ease of use compared to fludarabine regimens, and the superior efficacy vs chlorambucil, puts TREANDA in the sweet spot for potential front-line use in CLL.
Brian AbbottMay 19, 2008
National healthcare? Better find a new pool of physicians
Analysis of: Look to England's example for ways to solve America's health-care problem | www.sltrib.com
Author: Brian Abbott, Medical Director of Hematology, Big Sky Oncology
National healthcare has again become part of the presidential election dialog, after a curious 12+ year absence. Also curious, Hillary Clinton is again center stage in the discussion. Will the outcome be different this time?
Brian AbbottMay 19, 2008
Medicare: heading toward a crisis
Analysis of: Loss of Doctors Leaves Patients Waiting | www.redorbit.com
Author: Brian Abbott, Medical Director of Hematology, Big Sky Oncology
The aging population, coupled with per capita decreases in Medicare spending, threatens the entire health care system. Here's why.
May 19, 2008
The gods giveth and then takith away- Go figure.....
Analysis of: First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic EGFR Mutations | jco.ascopubs.org
Author: GLG Expert Contributor
Two papers, the one above, and http://jco.ascopubs.org/cgi/content/full/26/15/2450 reveal somewhat conflicting data on AstraZeneca's Iressa that was until now on the "back burner" due to Genentech's Tarceva, that had better response data than Iressa in separate trials On one hand the first paper points...
Donald FlemingMay 19, 2008
BRCA Mutations less risky than thought
Analysis of: Cancer-Gene Test Boosts Myriad's Sales | online.wsj.com
Author: Donald Fleming, Division Head of Hematology and Oncology, Davis Health System, Inc.
New data indicates risk of invasive breast cancer in women with either BRCA mutation maybe less than previuosly thought This new information will adversely impact Myriad's business
May 19, 2008
Alimta (Lilly): YES!!!!
Analysis of: Lilly Drug Shown to Slow Lung Cancer | online.wsj.com
Author: GLG Expert Contributor
That Alimta can be effectively used after other chemotherapy in non small cell lung cancer (NSCLC) as a maintenance agent!
May 15, 2008
Novo Nordisk: Good try but recombinant activated factor VII did not reach its goal in hemorrhagic stoke
Analysis of: Efficacy and Safety of Recombinant Activated Factor VII for Acute Intracerebral Hemorrhage | content.nejm.org
Author: GLG Expert Contributor
"In summary, rFVIIa reduced hematoma growth but did not reduce the rate of death or severe disability after intracerebral hemorrhage."
May 13, 2008
GSK: Gutsy but logical clinical trial of Tykerb v Herceptin (Genentech)
Analysis of: Glaxo Tests Tykerb vs Herceptin in Early Cancer | www.therapeuticsdaily.com
Author: GLG Expert Contributor
Glaxo is trying to move Tykerb ahead of Herceptin in a first line/neoajuvant/adjuvant setting in Her2Neu + Breast cancer.
May 12, 2008
ImClone: Does Morgan Stanley (MS) know something we don't??
Analysis of: US Drug Stocks Edge Higher, But ImClone Falls On Downgrade | news.ino.com
Author: GLG Expert Contributor
Erbitux was touted to have a positive study in Non Small Cell Lung Cancer (NSCLCA) but all they said was that is was a positive study. No further info at that time but an executive bought a block of stock a few days before the announcement which led to an inevitable rise in the stock price! Does this...

Previous Page : 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 Next131 to 140 of 889

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-05T01:45:24.617